Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1SLC9A3
The experimentally established mechanism targets of L-Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA4 | P22748 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Lactic Acid SCHEMBL29543519 | 1.00 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL9770204 | 1.00 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL145053 | 1.00 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL4737418 | 1.00 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL407161 | 1.00 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL4648043 | 0.96 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL29683322 | 0.96 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL29351424 | 0.96 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL4319 | 0.96 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL1532627 | 0.96 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3151 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144755-A1 | Solid Oral Dosage Forms Comprising Tavapadon | CEREVEL THERAPEUTICS, LLC (US) | 2026-05-28 | — | — | US | claimed |
| CN-119524126-A | Pharmaceutical resinated compositions and methods of making and using the same | 罗兹制药公司 | 2025-02-28 | — | — | CN | claimed |
| US-20240299412-A1 | DRUG FORMULATIONS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL) -3,5-DIHYDRO-2H-PYRIDO[3,4-f][1,4]OXAZEPINE-9-CARBONITRILE | GENZYME CORPORATION (US) | 2024-09-12 | — | — | US | claimed |
| US-20240293323-A1 | PHARMACEUTICAL COMPOSITIONS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR | BLUEPRINT MEDICINES CORPORATION | 2024-09-05 | — | — | US | claimed |
| EP-4358942-A1 | PHARMACEUTICAL COMPOSITIONS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR | Blueprint Medicines Corporation (US) | 2024-05-01 | — | — | EP | claimed |
| CN-117835970-A | Pharmaceutical composition of epidermal growth factor receptor inhibitor | 缆图药品公司 | 2024-04-05 | — | — | CN | claimed |
| CN-116803379-A | Indometazole immediate release/sustained release multilayer tablet and use thereof in the treatment of attention deficit/hyperactivity disorder (ADHD) | NLS-1 制药公司 | 2023-09-26 | — | — | CN | claimed |
| WO-2022271765-A1 | PHARMACEUTICAL COMPOSITIONS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | claimed |
| EP-4061340-A1 | ORAL SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING LANTHANUM CARBONATE OCTAHYDRATE | Santa Farma Ilaç Sanayi A.S. (TR) | 2022-09-28 | — | — | EP | claimed |
| US-20220162113-A1 | BORATE-GLASS COMPOSITIONS, METHODS OF MANUFACTURE, AND USES | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2022-05-26 | — | — | US | claimed |
| US-20020006919-A1 | Nanoparticulate eplerenone compositions | THOSAR SHILPA S (US) | 2002-01-17 | — | — | US | claimed |
| CN-1329494-A | Micronized eplerenone compositions | SEARLE & CO (US) | 2002-01-02 | — | — | CN | claimed |
| EP-1135139-A1 | MICRONIZED EPLERENONE COMPOSITIONS | G.D. SEARLE & CO. (US) | 2001-09-26 | — | — | EP | claimed |
| EP-1049467-A4 | CELECOXIB COMPOSITIONS | SEARLE & CO (US) | 2001-08-08 | — | — | EP | claimed |
| WO-2001041770-A2 | NANOPARTICULATE EPLERENONE COMPOSITIONS | PHARMACIA CORPORATION (US) | 2001-06-14 | — | — | WO | claimed |
| CN-1288378-A | Celecoxib compositions | SEARLE & CO (US) | 2001-03-21 | — | — | CN | claimed |
| EP-1049467-A1 | CELECOXIB COMPOSITIONS | G.D. Searle & Co. (US) | 2000-11-08 | — | — | EP | claimed |
| WO-2000033847-A1 | MICRONIZED EPLERENONE COMPOSITIONS | G.D. SEARLE & CO. (US) | 2000-06-15 | — | — | WO | claimed |
| WO-2000032189-A1 | CELECOXIB COMPOSITIONS | G. D. SEARLE & CO. (US) | 2000-06-08 | — | — | WO | claimed |
| EP-0563455-A1 | Particulate solid products containing a lump forming inhibitor | Purac Biochem B.V. (NL) | 1993-10-06 | — | — | EP | claimed |